Goals: Role of hormonal therapy (HT) is well established in node negative (N0) estrogen-receptor positive (ER+) early breast cancer (EBC). However benefit of chemotherapy (CT) in patients with N0, ER+ EBC would be small. Oncotype DX® (ODX) provides additional predictive and prognostic information beyond traditional clinical and pathological markers. International guidelines support use of Oncotype DX® test to evaluate risk of recurrence and predict the benefit of CT in ER+ EBC. Our goal is to examine and show health economic value and budget impact of ODX in a small group of patients (15 patients) with chemotherapy recommendation of the Tumor board – based on traditional clinical and pathological criteria.

Methods: Fifteen ODX tests were performed in selected HR+ EBC patients. Eligibility criteria for testing were: T1c, T2, N0, N1mi, ER+ (min. 50%) and HER-2 negative EBC. In addition 2 of the following criteria were allowed: Grade III histology, Ki67 >15%, LVI+, age <40 y. Patients with clear treatment preferences were excluded. Information about adjuvant treatment plan was collected before and after obtaining ODX Recurrence Score. There was an agreement that in case of a Recurrence Score (RS) lower than 25 – HT will be the choice of therapy. In cases when RS is equal to, or higher than 25 both CT+HT therapy will be administered (considering patient's preference in intermediate group). We registered treatment decisions before and after ODX tests. We calculated and compared total costs of registered treatments and side-effects without ODX and total costs of the treatments following ODX testing.

Results: Among women with EBC use of the ODX test changed treatment recommendations (from HT+CT to HT alone) in 64% of cases (9/14). Reimbursement criteria were not allowed use test for all eligible patients, but only patients with a doubt about the value of chemotherapy. We found 1 patient Her2+ by both ODX RT-PCR and IHC testing and was excluded from final evaluation. Based on preliminary data we found ICER = ?0.7 kEURO/QALY (these are intermediary results and final results will be presented in the poster).

Conclusion: We found ODX cost saving technology in selected ER+, EBC patients in Hungary. Final details, patients' characteristics and suggested treatments will be presented in frame of the poster. Zoltan Nagy has commercial relationship with Genomic Health Inc.